Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cody J Peer

Showing results (101-110 of 140) with videos related to

Pageof 14
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|June 20, 2020
Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing RegimenEleanor Jing Yi Cheong, Pramod C Nair, Rebecca Wan Yi Neo, et al.
Molecular Cancer Research : MCR|September 15, 2021
Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma ModelAmélie Vézina, Monica Manglani, DreeAnna Morris, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 25, 2024
Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicityMichele Ceribelli, Frances Anne Tosto, Xiaohu Zhang, et al.
Pharmacogenetics and Genomics|November 1, 2012
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel responseJoshua P Lewis, Richard B Horenstein, Kathleen Ryan, et al.
Clinical Immunology (Orlando, Fla.)|October 1, 2014
Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphomaJonathan L Berkowitz, John E Janik, Donn M Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational studyAnish Thomas, Arun Rajan, Eva Szabo, et al.
Pediatric Blood & Cancer|August 12, 2021
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumorsHolly J Meany, Brigitte C Widemann, Pamela S Hinds, et al.
Molecular Cancer Therapeutics|November 5, 2021
Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in <i>H/NRAS</i> Mutant RhabdomyosarcomaNatalia Garcia, Vanessa Del Pozo, Marielle E Yohe, et al.
Cancer|September 2, 2020
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelinRaffit Hassan, Christine Alewine, Idrees Mian, et al.
Frontiers in Oncology|May 6, 2024
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancersNebojsa Skorupan, Cody J Peer, Xianyu Zhang, et al.
Pageof 14

Showing results (101-110 of 140) with videos related to

Sort By:
Pageof 14
The Journal of Pharmacology and Experimental Therapeutics|June 20, 2020
Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing RegimenEleanor Jing Yi Cheong, Pramod C Nair, Rebecca Wan Yi Neo, et al.
Molecular Cancer Research : MCR|September 15, 2021
Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma ModelAmélie Vézina, Monica Manglani, DreeAnna Morris, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 25, 2024
Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicityMichele Ceribelli, Frances Anne Tosto, Xiaohu Zhang, et al.
Pharmacogenetics and Genomics|November 1, 2012
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel responseJoshua P Lewis, Richard B Horenstein, Kathleen Ryan, et al.
Clinical Immunology (Orlando, Fla.)|October 1, 2014
Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphomaJonathan L Berkowitz, John E Janik, Donn M Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational studyAnish Thomas, Arun Rajan, Eva Szabo, et al.
Pediatric Blood & Cancer|August 12, 2021
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumorsHolly J Meany, Brigitte C Widemann, Pamela S Hinds, et al.
Molecular Cancer Therapeutics|November 5, 2021
Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in <i>H/NRAS</i> Mutant RhabdomyosarcomaNatalia Garcia, Vanessa Del Pozo, Marielle E Yohe, et al.
Cancer|September 2, 2020
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelinRaffit Hassan, Christine Alewine, Idrees Mian, et al.
Frontiers in Oncology|May 6, 2024
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancersNebojsa Skorupan, Cody J Peer, Xianyu Zhang, et al.
Pageof 14